Enabling Genomic Testing in Cancer of Unknown Primary (EGG-CUP)

The Christie NHS Foundation Trust0 sites100 target enrollmentAugust 15, 2024

Overview

No summary available.

Registry

who.int

Start Date

August 15, 2024

End Date

February 11, 2028

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

•1\. Aged 16 years or over
•2\. Written informed consent according to Good Clinical Practice (GCP) and national regulations
•3\. Eastern Cooperative Oncology Group (ECOG) Performance status 0\-2
•4\. Confirmed diagnosis of CUP as per the European Society for Medical Oncology (ESMO) guidelines. Patients must have:
•4\.1\. The local pathology reports confirming compatibility with CUP diagnosis and the associated slides used for the diagnosis
•4\.2\. Discussion at a local CUP MDT confirming diagnosis
•5\. Availability of archival tumour histological report.
•6\. Willingness to provide blood samples on up to two occasions during the study

•1\. Patient with an immunohistochemistry profile that provides a definitive clinical indication of a primary cancer with a specific treatment
•2\. Known HIV, Hepatitis B, C positive, due to the difficulties in handling high\-risk specimens
•3\. Patients who are unable to provide fully informed written consent
•4\. Presence of any medical, psychological, familial or sociological condition that, in the investigator’s opinion, will hamper compliance with the study protocol and follow\-up schedule
•5\. Bleeding diathesis (patients on anticoagulation are permitted to enter the trial if anticoagulation can be safely managed to enable blood sampling)
•6\. Conditions in which blood sampling may increase the risk of complications for the patients and/or investigator